BACKGROUND AND AIMS: Approximately 10% of pancreatic adenocarcinoma is familial. Approximately 50% of 1st-degree relatives (FDRs) have endoscopic ultrasound (EUS) findings of chronic pancreatitis. We modeled the natural history of these patients to compare 4 management strategies. METHODS: We performed a systematic review, and created a Markov model for 45-year-old male FDRs, with findings of chronic pancreatitis on screening EUS. We compared 4 strategies: doing nothing, prophylactic total pancreatectomy (PTP), annual surveillance by EUS, and annual surveillance with EUS and fine needle aspiration (EUS/FNA). Outcomes incorporated mortality, quality of life, procedural complications, and costs. RESULTS: In the Do Nothing strategy, the lifetime risk of cancer was 20%. Doing nothing provided the greatest remaining years of life, the lowest cost, and the greatest remaining quality-adjusted life years (QALYs). PTP provided the fewest remaining years of life, and the fewest remaining QALYs. Screening with EUS provided nearly identical results to PTP, and screening with EUS/FNA provided intermediate results between PTP and doing nothing. PTP provided the longest life expectancy if the lifetime risk of pancreatic cancer was at least 46%, and provided the most QALYs if the risk was at least 68%. CONCLUSIONS: FDRs from familial pancreatic cancer kindreds, who have EUS findings of chronic pancreatitis, have increased risk for cancer, but their precise risk is unknown. Without the ability to further quantify that risk, the most effective strategy is to do nothing. (c) 2007 S. Karger AG, Basel and IAP.
BACKGROUND AND AIMS: Approximately 10% of pancreatic adenocarcinoma is familial. Approximately 50% of 1st-degree relatives (FDRs) have endoscopic ultrasound (EUS) findings of chronic pancreatitis. We modeled the natural history of these patients to compare 4 management strategies. METHODS: We performed a systematic review, and created a Markov model for 45-year-old male FDRs, with findings of chronic pancreatitis on screening EUS. We compared 4 strategies: doing nothing, prophylactic total pancreatectomy (PTP), annual surveillance by EUS, and annual surveillance with EUS and fine needle aspiration (EUS/FNA). Outcomes incorporated mortality, quality of life, procedural complications, and costs. RESULTS: In the Do Nothing strategy, the lifetime risk of cancer was 20%. Doing nothing provided the greatest remaining years of life, the lowest cost, and the greatest remaining quality-adjusted life years (QALYs). PTP provided the fewest remaining years of life, and the fewest remaining QALYs. Screening with EUS provided nearly identical results to PTP, and screening with EUS/FNA provided intermediate results between PTP and doing nothing. PTP provided the longest life expectancy if the lifetime risk of pancreatic cancer was at least 46%, and provided the most QALYs if the risk was at least 68%. CONCLUSIONS: FDRs from familial pancreatic cancer kindreds, who have EUS findings of chronic pancreatitis, have increased risk for cancer, but their precise risk is unknown. Without the ability to further quantify that risk, the most effective strategy is to do nothing. (c) 2007 S. Karger AG, Basel and IAP.
Authors: G Anton Decker; Mashal J Batheja; Joseph M Collins; Alvin C Silva; Kristin L Mekeel; Adyr A Moss; Cuong C Nguyen; Douglas F Lake; Laurence J Miller Journal: Gastroenterol Hepatol (N Y) Date: 2010-04
Authors: Wesley H Greenblatt; Chin Hur; Amy B Knudsen; John A Evans; Daniel C Chung; G Scott Gazelle Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-29 Impact factor: 4.254
Authors: Michelle A Anderson; Eugene Zolotarevsky; Kristine L Cooper; Simon Sherman; Oleg Shats; David C Whitcomb; Henry T Lynch; Paola Ghiorzo; Wendy S Rubinstein; Kristen J Vogel; Aaron R Sasson; William E Grizzle; Marsha A Ketcham; Shih-Yuan Lee; Daniel Normolle; Caitlyn M Plonka; Amy N Mertens; Renee C Tripon; Randall E Brand Journal: Am J Gastroenterol Date: 2012-08-28 Impact factor: 10.864